Australian Drug Maker Has Low Profile but Powerful Backers in Washington
7:37am PDT - August 8th, 2018 chris collins - The New York TimesRepresentatives Chris Collins and Tom Price and other power players have substantial investments in Innate Immunotherapeutics, a company with no approved drugs.